Last edition
News about
UPS Healthcare Opens Logistics Facility in Dublin with EUR 12 Million Investment
The new Dublin facility, fitted with specialized technology, offers in-demand storage and inbound and outbound transportation for a range of pharmaceutical and health tech products.
Telo Genomics and Emery Pharma Announce Collaboration to Enhance Oncology Testing
This partnership aims to offer complementary cellular and molecular bioanalytical solutions for clinical research and development initiatives to their respective clients.
SII Invests in IntegriMedical to Boost N-FIS Technology
Serum Institute of India (SII) has made a strategic investment in IntegriMedical, acquiring a 20 percent stake in the company, to advance Needle-Free Injection System technology.
Lupin Gets Approval from US FDA for Midostaurin Capsules
Lupin has secured approval from the United States Food and Drug Administration (US FDA) for its Abbreviated New Drug Application for Midostaurin Capsules.
The EVIS X1 endoscopy system features imaging technologies designed to help physicians diagnose, treat and observe diseases and disorders of the upper and lower GI tract, including colorectal cancer.
Johnson & Johnson to Acquire Proteologix to Expand its Portfolio
Johnson & Johnson has signed a definitive agreement to acquire Proteologix, Inc. for USD 850 million in cash, with the potential for an additional milestone payment.
Bristol Myers Squibb Gets US FDA Approval for Breyanzi
Bristol Myers Squibb has declared that US Food and Drug Administration (FDA) has granted accelerated approval for Breyanzi.
FX Shoulder Solutions Secures FDA Clearance for Full-Wedge Augmented Glenoid Baseplates
This clearance brings the total number of glenoid baseplate options to 18, providing a variety of solutions for surgeons addressing bone loss, defects, or complicated glenoid morphologies.
FDA Approves Amgen's IMDELLTRA for Advanced Small Cell Lung Cancer
The approval is based on the encouraging response rate and duration of response (DoR) observed in clinical studies, under the FDA's accelerated approval pathway.
Granules India Records 2 Percent Growth in Revenue from Operations in Q4FY24
Granules India Ltd., has announced its financial results for the quarter and financial year ended March 31, 2024.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy